Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08FNJ
|
|||
Former ID |
DIB006001
|
|||
Drug Name |
RO-14
|
|||
Synonyms |
Very low molecular weight heparin (venous thromboembolism), Rovi
Click to Show/Hide
|
|||
Indication | Phlebothrombosis [ICD-11: GB90.3; ICD-10: I80-I82] | Phase 1 | [1] | |
Company |
Laboratorios Farmaceuticos Rovi SA
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Antithrombin-III (ATIII) | Target Info | Modulator | [2] |
KEGG Pathway | Complement and coagulation cascades | |||
Panther Pathway | Blood coagulation | |||
Pathway Interaction Database | Glypican 1 network | |||
Reactome | Intrinsic Pathway of Fibrin Clot Formation | |||
Common Pathway of Fibrin Clot Formation | ||||
WikiPathways | Complement and Coagulation Cascades | |||
Formation of Fibrin Clot (Clotting Cascade) |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT00629733) Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers. U.S. National Institutes of Health. | |||
REF 2 | Pharmacological effects and clinical applications of ultra low molecular weight heparins. Drug Discov Ther. 2014 Feb;8(1):1-10. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.